Skip to content
OpenCapital
Get started

Alto Neuroscience ANRO Q1 2026 earnings

Reported May 13, 2026 · Before market open

EPS-$0.80Miss by $0.24
EPS estimate-$0.56

Next report

Aug 12, 2026 (In 2 weeks)
EPS estimate-$0.71

Financials

Q1 2026

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$1.08B+1,195%
Enterprise value$839.94M-2,247%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Versus estimates

Diluted EPS

Q1 2026-$0.80Miss by $0.24
Q4 2025-$0.45Beat by $0.11Q3 2025-$0.52Beat by $0.14Q2 2025-$0.65Miss by $0.08Q1 2025-$0.53Beat by $0.06Q4 2024-$0.56Beat by $0.09

Ask the moment Alto Neuroscience reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Alto Neuroscience report Q1 2026 earnings?
Alto Neuroscience (ANRO) reported Q1 2026 earnings on May 13, 2026 before market open.
What were Alto Neuroscience's Q1 2026 revenue and EPS?
Alto Neuroscience reported eps of $-0.80 for Q1 2026.
Did Alto Neuroscience beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.56 by $0.24.
How did Alto Neuroscience's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 50.9% from $-0.53.
Where can I find Alto Neuroscience's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001999480-26-000011) and the 10-Q periodic report (0001999480-26-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.